Related Experiment Video
Updated: Jul 1, 2026
06:07
Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
Azacytidine causes complex DNA methylation responses in myeloid leukemia
Carlo Stresemann1, Imke Bokelmann, Ulrich Mahlknecht
1Division of Epigenetics, German Cancer Research Center, Germany.
Molecular Cancer Therapeutics
|September 16, 2008
Summary
Azacitidine therapy for myelodysplastic syndrome (MDS) causes DNA demethylation in patients. This study characterizes these epigenetic changes, revealing patient-specific responses to azacitidine treatment.
Area of Science:
- Epigenetics
- Hematologic Malignancies
- Pharmacology
Background:
- Aberrant DNA methylation is crucial in hematologic malignancies.
- DNA methyltransferase inhibitors like azacitidine show clinical benefits for myelodysplastic syndrome (MDS).
- The exact mechanism of action for these drugs, particularly in patients, requires further elucidation.
Purpose of the Study:
- To analyze azacitidine-induced DNA demethylation responses in myeloid leukemia cell lines.
- To characterize drug-induced methylation changes in MDS patients undergoing azacitidine therapy.
- To provide proof-of-mechanism data for azacitidine's demethylating activity in MDS.
Main Methods:
- Analysis of azacitidine-induced demethylation in myeloid leukemia cell lines.
- Assessment of DNA methyltransferase depletion and demethylation responses.
- DNA methylation analysis of blood and bone marrow samples from MDS patients receiving azacitidine.
Main Results:
- Myeloid leukemia cell lines exhibited varied DNA methyltransferase depletion and demethylation responses to azacitidine.
- MDS patients showed significant inter-individual differences in epigenetic responses to azacitidine therapy.
- Transient, significant demethylation was observed in 3 of 6 patients, impacting numerous hypermethylated loci.
Conclusions:
- Azacitidine demonstrates demethylating activity in MDS patients, supporting its therapeutic mechanism.
- Patient responses to azacitidine-induced demethylation are complex and highly variable.
- These findings offer detailed insights into the epigenetic reprogramming caused by azacitidine in MDS.
Related Concept Videos
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:17Phase II Reactions: Methylation Reactions
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
01:37Epigenetic Regulation
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
01:46Epigenetic Regulation
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
01:28Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...